Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
3.818
-0.217 (-5.38%)
Apr 27, 2026, 12:28 PM EDT - Market open
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change
1
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,839,857
Market Cap
3.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% |
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
| GRI Bio | 4 |
ARTL News
- 7 days ago - Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile - GlobeNewsWire
- 20 days ago - Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 27 days ago - Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Stock Soars After Withdrawing SEC Filing - Benzinga
- 4 weeks ago - Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength - GlobeNewsWire
- 5 weeks ago - Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites Rally - Benzinga